Plantaricin A

Plantaricin A is an antimicrobial peptide that can be derived from Lactobacillus plantarum. Plantaricin A has a synergistic effect with Ciprofloxacin. Plantaricin A shows anti-microbial activity. Plantaricin A increases the membrane potential of S. aureus and the level of intracellular ROS. Plantaricin A inhibits the function of the efflux pump by binding it and altering the structure of MepA, NorA, and LmrS. Plantaricin A significantly relieves inflammation, and promotes wound healing. Plantaricin A permeabilizes cancerous rat pituitary cells[1][2].

Product Specifications

CAS Number

[131463-18-8]

Product Name Alternative

PlnA

UNSPSC

12352209

Target

Bacterial; Reactive Oxygen Species (ROS)

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/plantaricin-a.html

Purity

99.45

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(NCC(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(NCC(N[C@@H](CC5=CNC6=CC=CC=C56)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N

Molecular Formula

C140H222N36O34S

Molecular Weight

2985.55

References & Citations

[1]Meng F, et al. Plantaricin A reverses resistance to ciprofloxacin of multidrug-resistant Staphylococcus aureus by inhibiting efflux pumps. Environ Microbiol. 2022 Oct;24 (10) :4818-4833. |[2]Sand SL, et al. Plantaricin A, a peptide pheromone produced by Lactobacillus plantarum, permeabilizes the cell membrane of both normal and cancerous lymphocytes and neuronal cells. Peptides. 2010 Jul;31 (7) :1237-44.